These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 27692568)

  • 1. Effect of over-2-year dual antiplatelet therapy on the rate of major adverse cardiac and cerebral events for everolimus-eluting stent implantation: The landmark analysis from Tokyo-MD PCI registry.
    Ueshima D; Ashikaga T; Yoshikawa S; Sasaoka T; Hatano Y; Kurihara K; Maejima Y; Isobe M
    J Cardiol; 2017 Jun; 69(6):815-822. PubMed ID: 27692568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
    Hong SJ; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Her AY; Kim YH; Jang Y; Hong MK;
    JACC Cardiovasc Interv; 2016 Jul; 9(14):1438-46. PubMed ID: 27212028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants and Clinical Outcomes of Extended Dual Antiplatelet Therapy over 3 Years after Drug-Eluting Stent Implantation: A Retrospective Analysis.
    Lee OH; Kim BK; Hong SJ; Kim S; Ahn CM; Shin DH; Kim JS; Kang TS; Ko YG; Choi D; Hong MK; Jang Y
    Yonsei Med J; 2020 Jul; 61(7):597-605. PubMed ID: 32608203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease.
    Lee HJ; Yu CW; Hwang HK; Choi RK; Park JS; Li H; Ro YM
    Coron Artery Dis; 2013 Nov; 24(7):542-8. PubMed ID: 23994880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
    Hermiller JB; Krucoff MW; Kereiakes DJ; Windecker S; Steg PG; Yeh RW; Cohen DJ; Cutlip DE; Massaro JM; Hsieh WH; Mauri L;
    JACC Cardiovasc Interv; 2016 Jan; 9(2):138-47. PubMed ID: 26793956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of clopidogrel-based dual antiplatelet therapy and clinical outcomes after endeavor sprint zotarolimus-eluting stent implantation in patients presenting with acute coronary syndrome.
    Song PS; Hahn JY; Kim DI; Song YB; Choi SH; Choi JH; Ryu DR; Hur SH; Jeong JO; Park HS; Kim HS; Gwon HC
    Eur J Intern Med; 2015 Sep; 26(7):521-7. PubMed ID: 26153337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
    Gilard M; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berland J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Endresen K; Benamer H; Kiss RG; Ungi I; Boschat J; Morice MC
    J Am Coll Cardiol; 2015 Mar; 65(8):777-786. PubMed ID: 25461690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies.
    Sorrentino S; Claessen BE; Chandiramani R; Guedeney P; Vogel B; Baber U; Rau V; Wang J; Krucoff M; Kozuma K; Ge J; Seth A; Makkar R; Liu Y; Bangalore S; Bhatt DL; Angiolillo DJ; Saito S; Neumann FJ; Hermiller J; Valgimigli M; Mehran R
    Circulation; 2020 Mar; 141(11):891-901. PubMed ID: 31992063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies.
    Yoshikawa Y; Shiomi H; Watanabe H; Natsuaki M; Kondo H; Tamura T; Nakagawa Y; Morimoto T; Kimura T
    Circulation; 2018 Feb; 137(6):551-562. PubMed ID: 28982692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.
    Kereiakes DJ; Yeh RW; Massaro JM; Driscoll-Shempp P; Cutlip DE; Steg PG; Gershlick AH; Darius H; Meredith IT; Ormiston J; Tanguay JF; Windecker S; Garratt KN; Kandzari DE; Lee DP; Simon DI; Iancu AC; Trebacz J; Mauri L;
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1552-62. PubMed ID: 26493248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Impact of prolonging dual antiplatelet therapy on long-term prognosis of elderly patients with coronary heart disease complicated with diabetes mellitus undergoing drug-eluting stent implantation].
    Xu JJ; Zhu P; Song Y; Yuan DS; Jia SD; Zhao XY; Yao Y; Jiang L; Xu N; Li JX; Zhang Y; Song L; Gao LJ; Chen JL; Qiao SB; Yang YJ; Xu B; Gao RL; Yuan JQ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 May; 50(5):450-457. PubMed ID: 35589593
    [No Abstract]   [Full Text] [Related]  

  • 12. Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention.
    Yamamoto K; Watanabe H; Morimoto T; Obayashi Y; Natsuaki M; Yamaji K; Domei T; Ogita M; Ohya M; Tatsushima S; Suzuki H; Tada T; Ishii M; Nikaido A; Watanabe N; Fujii S; Mori H; Nishikura T; Suematsu N; Hayashi F; Komiyama K; Shigematsu T; Isawa T; Suwa S; Ando K; Kimura T;
    JACC Cardiovasc Interv; 2023 Jan; 16(1):19-31. PubMed ID: 36599584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial.
    Natsuaki M; Morimoto T; Yamamoto E; Shiomi H; Furukawa Y; Abe M; Nakao K; Ishikawa T; Kawai K; Yunoki K; Shimizu S; Akao M; Miki S; Yamamoto M; Okada H; Hoshino K; Kadota K; Morino Y; Igarashi K; Tanabe K; Kozuma K; Kimura T
    Cardiovasc Interv Ther; 2016 Jul; 31(3):196-209. PubMed ID: 26518420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of dual antiplatelet therapy use in patients following everolimus-eluting stent implantation: insights from the SEEDS study.
    Zhang YJ; Zhao YL; Xu B; Han YL; Li B; Liu Q; Su X; Pang S; Lu SZ; Guo XF; Yang YJ
    Chin Med J (Engl); 2015 Mar; 128(6):714-20. PubMed ID: 25758261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial.
    Min PK; Kang TS; Cho YH; Cheong SS; Kim BK; Kwon SW; Park WJ; Lee JH; Kim W; Lee WS; Yoon YW; Lee BK; Kwon HM; Hong BK;
    JAMA Netw Open; 2024 Mar; 7(3):e240877. PubMed ID: 38451525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clopidogrel Monotherapy vs. Aspirin Monotherapy Following Short-Term Dual Antiplatelet Therapy in Patients Receiving Everolimus-Eluting Coronary Stent Implantation.
    Natsuaki M; Morimoto T; Watanabe H; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Igarashi Hanaoka K; Morino Y; Kozuma K; Kadota K; Kimura T;
    Circ J; 2020 Aug; 84(9):1483-1492. PubMed ID: 32684537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation.
    Mehran R; Cao D; Angiolillo DJ; Bangalore S; Bhatt DL; Ge J; Hermiller J; Makkar RR; Neumann FJ; Saito S; Picon H; Toelg R; Maksoud A; Chehab BM; De la Torre Hernandez JM; Kunadian V; Sardella G; Thiele H; Varenne O; Vranckx P; Windecker S; Zhou Y; Krucoff MW; Ruster K; Wang J; Valgimigli M;
    JACC Cardiovasc Interv; 2021 Sep; 14(17):1870-1883. PubMed ID: 34503737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.
    Mehran R; Baber U; Steg PG; Ariti C; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Berger PB; Iakovou I; Dangas G; Waksman R; Antoniucci D; Sartori S; Krucoff MW; Hermiller JB; Shawl F; Gibson CM; Chieffo A; Alu M; Moliterno DJ; Colombo A; Pocock S
    Lancet; 2013 Nov; 382(9906):1714-22. PubMed ID: 24004642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.